Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (20) , 4509-4512
Abstract
No abstract availableKeywords
Funding Information
- US National Institutes of Health (SC2GM109782, T32GM105538)
- American Cancer Society Institutional Research (93-037-18)
This publication has 13 references indexed in Scilit:
- Development of Rhodesain Inhibitors with a 3‐Bromoisoxazoline WarheadChemMedChem, 2013
- Inhibition of Rhodesain as a Novel Therapeutic Modality for Human African TrypanosomiasisJournal of Medicinal Chemistry, 2013
- Chemical–biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-targetBeilstein Journal of Organic Chemistry, 2013
- Fragment-Based Approaches in Drug Discovery and Chemical BiologyBiochemistry, 2012
- Trypanosoma brucei: Chemical evidence that cathepsin L is essential for survival and a relevant drug targetInternational Journal for Parasitology, 2012
- Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping SicknessAntimicrobial Agents and Chemotherapy, 2011
- Identification and Optimization of Inhibitors of Trypanosomal Cysteine Proteases: Cruzain, Rhodesain, and TbCatBJournal of Medicinal Chemistry, 2009
- Recent Developments in Fragment-Based Drug DiscoveryJournal of Medicinal Chemistry, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Fragment-based lead discoveryNature Reviews Drug Discovery, 2004